Cargando…
Imatinib resistance: a review of alternative inhibitors in chronic myeloid leukemia
The development of point mutations in the BCR-ABL kinase domain is the main reason for imatinib resistance in chronic myeloid leukemia. Different detection methods are used in chronic myeloid leukemia monitoring, such as direct sequencing, denaturing high performance liquid chromatography and allele...
Autores principales: | Bitencourt, Roberta, Zalcberg, Ilana, Louro, Iúri Drumond |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Associação Brasileira de Hematologia e Hemoterapia
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3459369/ https://www.ncbi.nlm.nih.gov/pubmed/23049365 http://dx.doi.org/10.5581/1516-8484.20110124 |
Ejemplares similares
-
Is the BCR-ABL/GUSB transcript level at diagnosis an early predictive marker for chronic myeloid leukemia patients treated with imatinib?
por: Bonecker, Simone, et al.
Publicado: (2015) -
Imatinib in Chronic Myeloid Leukemia: an Overview
por: Sacha, Tomasz
Publicado: (2014) -
Targeted treatment of imatinib-resistant chronic myeloid leukemia: Focus on dasatinib
por: Chuah, Charles, et al.
Publicado: (2009) -
The significance of major and stable molecular responses in chronic myeloid leukemia in the tyrosine kinase inhibitor era
por: Renault, Ilana Zalcberg, et al.
Publicado: (2011) -
Targeted treatment of chronic myeloid leukemia: role of imatinib
por: Tamascar, Ila, et al.
Publicado: (2009)